Kinase inhibitors targeting oncogenic v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) genes are also associated with a high ORR and improved survival for patients with advanced melanoma when received as a monotherapy or in combination with mitogen-activated protein kinase (MEK) inhibitors (8). Here, BRAF is linked to melanoma.